Back to results
US 2024/0197788 A1Published application
Pharmaceutical composition for preventing or treating parkinson's disease, and preparation method thereof
AssigneeIndustry Foundation of Chonnam National University
InventorsHAN SEONG JEONG, SU JEONG JANG, HYONG HO CHO, RAMALINGAM MAHESH
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition utilizes a cultured product obtained by differentiating a mesenchymal stem cell into a neuron. The pharmaceutical composition may be used to treat Parkinson's disease. The cultured product exhibits a preventive or therapeutic effect against Parkinson's disease by inhibiting dopaminergic neuron apoptosis by reducing insoluble alpha-synuclein aggregated in the neuron.
Claims19
1:
- A pharmaceutical composition comprising:
- a first culture which includes mesenchymal stem cells;
- and
- a second culture obtained by sequentially adding basic fibroblast growth factor (bFGF) and forskolin to the first culture, and then culturing the same.
1 more element
2:
- The pharmaceutical composition according to claim 1, wherein the second culture does not include cells, which are separated therefrom.
3:
- The pharmaceutical composition according to claim 1, wherein the mesenchymal stem cells are mesenchymal stem cells derived from human or animal bone marrow, fat, placenta, umbilical cord blood, or peripheral blood.
4:
- The pharmaceutical composition according to claim 1, wherein the bFGF is added at a concentration of 20 to 150 ng/ml.
5:
- The pharmaceutical composition according to claim 1, wherein the forskolin is added after 5 to 10 days from the addition of the bFGF.
6:
- The pharmaceutical composition according to claim 1, wherein the forskolin is added at a concentration of 5 to 15 μM.
7:
- The pharmaceutical composition according to claim 1, wherein the second culture is cultured for 3 to 8 days from the addition of forskolin.
8:
- A method for production of a pharmaceutical composition, the method comprising:
- adding basic fibroblast growth factor (bFGF) to a first culture which includes mesenchymal stem cells;
- and
- adding forskolin to the first culture treated with the bFGF.
1 more element
9:
- The method according to claim 8, further comprising removing the mesenchymal stem cells from the forskolin-treated culture.
10:
- The method according to claim 8, wherein the mesenchymal stem cells are mesenchymal stem cells derived from bone marrow, fat, placenta, umbilical cord blood, or peripheral blood of humans or animals.
11:
- The method according to claim 8, wherein the bFGF is added at a concentration of 20 to 150 ng/ml.
12:
- The method according to claim 8, wherein the forskolin is added after 5 to 10 days from the addition of the bFGF.
13:
- The method according to claim 8, wherein the forskolin is added at a concentration of 5 to 15 μM.
14:
- The method according to claim 8, further comprising culturing the culture for 3 to 8 days after the addition of the forskolin.
15:
- A method for treatment of Parkinson's disease, the method comprising:
- sequentially adding basic fibroblast growth factor (bFGF) and forskolin to a first culture including mesenchymal stem cells and culturing the same to obtain a second culture;
- and
- treating a subject in need thereof with the second culture.
1 more element
16:
- The method according to claim 15, wherein the bFGF is added at a concentration of 20 to 150 ng/ml.
17:
- The method according to claim 15, wherein the forskolin is added after 5 to 10 days from the addition of the bFGF.
18:
- The method according to claim 15, wherein the forskolin is added at a concentration of 5 to 15 μM.
19:
- The method according to claim 15, wherein the culturing is performed for 3 to 8 days after the addition of the forskolin.